EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: TRK fusions are oncogenic drivers in a variety of tumors, many involving the CNS. Larotrectinib, a selective FDA- and EMA-approved TRK inhibitor, demonstrated a 79% objective response rate (ORR) and a 35.2-month median duration of response (DoR) in adult and pediatric patients with vario...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Hiroaki, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Schulte, Johannes, Kang, Hyoung Jin, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Reeves, John A, Brega, Nicoletta, Childs, Barrett H, Laetsch, Theodore W, Ziegler, David S, Doz, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715507/
http://dx.doi.org/10.1093/neuonc/noaa222.132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715507/
http://dx.doi.org/10.1093/neuonc/noaa222.132

Ejemplares similares